Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 509 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asthma Control Clear all
Completed Phase 3 Interventional Results available

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

NCT00588406
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, albuterol, Ipratropium bromide, Prednisone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
East Meadow, New York • Queens, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

NCT01573624
View directory record Official record
Conditions
Asthma
Interventions
FF/GSK573719, FF, FF/VI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

NCT00044824
View directory record Official record
Conditions
Asthma
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

NCT03084718
View directory record Official record
Conditions
Asthma
Interventions
CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
134
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 4, 2026, 1:04 AM EDT
Not listed No phase listed Observational

Creation of Home-based Asthma Real-World Measures With Mobile Health Study

NCT04462224
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

NCT05281523
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Tucson, Arizona • Roseville, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00838591
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Loma Linda, California • San Diego, California • Sylmar, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

NCT02748642
View directory record Official record
Conditions
Mild Atopic Asthma
Interventions
BITS7201A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

NCT02040766
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
75
States / cities
Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

NCT01545440
View directory record Official record
Conditions
Asthma
Interventions
lebrikizumab, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
70
States / cities
Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

NCT02433834
View directory record Official record
Conditions
Asthma
Interventions
Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.

NCT00600171
View directory record Official record
Conditions
Asthma
Interventions
GW642444M, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • Huntington Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 4, 2026, 1:04 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

NCT01577628
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Asthma, Food Allergies, Allergic Rhinitis
Interventions
Lipikar Balm AP
Drug
Lead sponsor
Cosmetique Active International
Industry
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Canton, Michigan • Fort Gratiot, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

School-Based Telemedicine Enhanced Asthma Management

NCT01650844
View directory record Official record
Conditions
Pediatric Asthma
Interventions
School-Based Telemedicine Enhanced Asthma Management, Enhanced Usual Care
Other
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 10 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Self-regulation for Older Adults With Asthma Through Remote Education

NCT05722834
View directory record Official record
Conditions
Asthma
Interventions
SOAR intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

A Study of RO4989991 in Patients With Allergic Rhinitis

NCT01152619
View directory record Official record
Conditions
Asthma
Interventions
Placebo, RO4989991
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
South Miami, Florida • Normal, Illinois • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 4, 2026, 1:04 AM EDT
Terminated Phase 4 Interventional Results available

Azithromycin for Children Hospitalized With Asthma

NCT02003911
View directory record Official record
Conditions
Asthma
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
4 Years to 12 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

NCT01479595
View directory record Official record
Conditions
Asthma
Interventions
QBX258, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Anaheim, California • Riverside, California • Rolling Hills Estates, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 3 Interventional

A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities

NCT00935077
View directory record Official record
Conditions
Hypertension, Asthma
Interventions
PPCM Asthma, 24 Month PPCM BP, 9 Month PPCM BP
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
1,441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
28
States / cities
San Diego, California • Hartford, Connecticut • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Pharmacokinetics of QAW039

NCT01253603
View directory record Official record
Conditions
Persistent Asthma
Interventions
QAW039 capsules once daily for 28 days, Placebo to QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 1 Interventional

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

NCT01113034
View directory record Official record
Conditions
Asthma, Bronchiectasis
Interventions
DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 4, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
View directory record Official record
Conditions
Asthma
Interventions
SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 4, 2026, 1:04 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00683449
View directory record Official record
Conditions
Asthma, Status Asthmaticus
Interventions
Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Sylmar, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Sep 4, 2026, 1:04 AM EDT